Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemic patients

D Kobayashi1, N Watanabe, N Yamauchi

  • 1Department of Laboratory Diagnosis, Sapporo Medical University, School of Medicine, Chuo-ku, Japan.

Blood
|April 1, 1997
PubMed

Insights

Intracellular tumor necrosis factor (enTNF) drives resistance to doxorubicin (DOX) in leukemia by increasing manganous superoxide dismutase (MnSOD). Elevated enTNF predicts poor response to DOX chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Intracellular tumor necrosis factor (enTNF) confers resistance to doxorubicin (DOX), exogenous TNF, and heat stress.
  • enTNF induces manganous superoxide dismutase (MnSOD), which scavenges reactive oxygen free radicals, contributing to chemoresistance.

Purpose of the Study:

  • To investigate the correlation between enTNF expression, MnSOD activity, and doxorubicin (DOX) sensitivity in patient-derived leukemia cells.
  • To evaluate the role of enTNF as a potential predictor of DOX sensitivity in leukemia.

Main Methods:

  • Analysis of enTNF expression and MnSOD activity in leukemic cells from 19 patients (6 ALL, 13 AML).
  • Correlation of sensitivity to DOX and TNF with enTNF expression and MnSOD activity.
  • Transfection of KG-1 cells with a TNF expression vector and TNF antisense cDNA to assess DOX resistance and MnSOD levels.

Main Results:

  • Leukemia cell sensitivity to DOX was inversely correlated with enTNF expression and MnSOD activity.
  • Acquired chemoresistance cases showed increased enTNF expression and MnSOD activity.
  • Transfection with TNF antisense cDNA increased DOX sensitivity in leukemic cells (1.4- to 2.5-fold).

Conclusions:

  • enTNF functions as a resistance factor against doxorubicin (DOX) in leukemia.
  • enTNF expression levels may serve as a predictive biomarker for doxorubicin (DOX) sensitivity in leukemia patients.